A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai, Samantha Jaglowski, Nandita D Khera, Jeanne Palmer, George L. Chen, Madan H. Jagasia, Sebastian A. Mayer, William A. Wood, Michael Green, Teresa S. Hyun, Yoshihiro Inamoto, Barry E. Storer, David B. Miklos, Howard M. Shulman, Paul J. Martin, Stefanie Sarantopoulos, Stephanie J. LeeMary E D Flowers

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: Weconducted a prospective,multicenter, randomized, two-armphase II crossover trial of imatinib (200mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrentmalignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%-43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%-44%) randomized to rituximab. Six (17%; 95% CI, 7%-34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%-29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab.

Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalClinical Cancer Research
Volume22
Issue number2
DOIs
StatePublished - Jan 15 2016

Fingerprint

Cell Transplantation
Sclerosis
Cross-Over Studies
Skin
Confidence Intervals
B-Lymphocytes
Therapeutics
Graft vs Host Disease
Articular Range of Motion
Imatinib Mesylate
Rituximab
Research Design
Quality of Life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. / Arai, Sally; Pidala, Joseph; Pusic, Iskra; Chai, Xiaoyu; Jaglowski, Samantha; Khera, Nandita D; Palmer, Jeanne; Chen, George L.; Jagasia, Madan H.; Mayer, Sebastian A.; Wood, William A.; Green, Michael; Hyun, Teresa S.; Inamoto, Yoshihiro; Storer, Barry E.; Miklos, David B.; Shulman, Howard M.; Martin, Paul J.; Sarantopoulos, Stefanie; Lee, Stephanie J.; Flowers, Mary E D.

In: Clinical Cancer Research, Vol. 22, No. 2, 15.01.2016, p. 319-327.

Research output: Contribution to journalArticle

Arai, S, Pidala, J, Pusic, I, Chai, X, Jaglowski, S, Khera, ND, Palmer, J, Chen, GL, Jagasia, MH, Mayer, SA, Wood, WA, Green, M, Hyun, TS, Inamoto, Y, Storer, BE, Miklos, DB, Shulman, HM, Martin, PJ, Sarantopoulos, S, Lee, SJ & Flowers, MED 2016, 'A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation', Clinical Cancer Research, vol. 22, no. 2, pp. 319-327. https://doi.org/10.1158/1078-0432.CCR-15-1443
Arai, Sally ; Pidala, Joseph ; Pusic, Iskra ; Chai, Xiaoyu ; Jaglowski, Samantha ; Khera, Nandita D ; Palmer, Jeanne ; Chen, George L. ; Jagasia, Madan H. ; Mayer, Sebastian A. ; Wood, William A. ; Green, Michael ; Hyun, Teresa S. ; Inamoto, Yoshihiro ; Storer, Barry E. ; Miklos, David B. ; Shulman, Howard M. ; Martin, Paul J. ; Sarantopoulos, Stefanie ; Lee, Stephanie J. ; Flowers, Mary E D. / A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 2. pp. 319-327.
@article{b0170d340c19402096df0dfa84ae292e,
title = "A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation",
abstract = "Purpose: Cutaneous sclerosis occurs in 20{\%} of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: Weconducted a prospective,multicenter, randomized, two-armphase II crossover trial of imatinib (200mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrentmalignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26{\%}; 95{\%} confidence interval (CI); 13{\%}-43{\%}] participants randomized to imatinib and 10 of 37 (27{\%}; 95{\%} CI, 14{\%}-44{\%}) randomized to rituximab. Six (17{\%}; 95{\%} CI, 7{\%}-34{\%}) patients in the imatinib arm and 5 (14{\%}; 95{\%} CI, 5{\%}-29{\%}) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab.",
author = "Sally Arai and Joseph Pidala and Iskra Pusic and Xiaoyu Chai and Samantha Jaglowski and Khera, {Nandita D} and Jeanne Palmer and Chen, {George L.} and Jagasia, {Madan H.} and Mayer, {Sebastian A.} and Wood, {William A.} and Michael Green and Hyun, {Teresa S.} and Yoshihiro Inamoto and Storer, {Barry E.} and Miklos, {David B.} and Shulman, {Howard M.} and Martin, {Paul J.} and Stefanie Sarantopoulos and Lee, {Stephanie J.} and Flowers, {Mary E D}",
year = "2016",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-15-1443",
language = "English (US)",
volume = "22",
pages = "319--327",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

AU - Arai, Sally

AU - Pidala, Joseph

AU - Pusic, Iskra

AU - Chai, Xiaoyu

AU - Jaglowski, Samantha

AU - Khera, Nandita D

AU - Palmer, Jeanne

AU - Chen, George L.

AU - Jagasia, Madan H.

AU - Mayer, Sebastian A.

AU - Wood, William A.

AU - Green, Michael

AU - Hyun, Teresa S.

AU - Inamoto, Yoshihiro

AU - Storer, Barry E.

AU - Miklos, David B.

AU - Shulman, Howard M.

AU - Martin, Paul J.

AU - Sarantopoulos, Stefanie

AU - Lee, Stephanie J.

AU - Flowers, Mary E D

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: Weconducted a prospective,multicenter, randomized, two-armphase II crossover trial of imatinib (200mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrentmalignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%-43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%-44%) randomized to rituximab. Six (17%; 95% CI, 7%-34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%-29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab.

AB - Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: Weconducted a prospective,multicenter, randomized, two-armphase II crossover trial of imatinib (200mg daily) or rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrentmalignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. Results: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%-43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%-44%) randomized to rituximab. Six (17%; 95% CI, 7%-34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%-29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27+) were seen at enrollment in rituximab-treated patients who had treatment success (P0.01), but not in imatinib-treated patients. Conclusions: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab.

UR - http://www.scopus.com/inward/record.url?scp=84958983532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958983532&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1443

DO - 10.1158/1078-0432.CCR-15-1443

M3 - Article

C2 - 26378033

AN - SCOPUS:84958983532

VL - 22

SP - 319

EP - 327

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -